Deregulation of p73 isoform equilibrium in benign prostate hyperplasia and prostate cancer

Oncology Reports

Volumn 12, Issue 5, 2004, Pages 1131-1137

  Arvanitis, Demetrios A ^a   Lianos, Emmanouel ^b   Soulitzis, Nikolaos ^a   Delakas, Demetrios ^b   Spandidos, Demetrios A ^a  

^a UNIVERSITY OF CRETE   (Greece)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Apoptosis; Cell cycle; p73 exon 13; p73Deltaexon2

Indexed keywords

BETA 2 MICROGLOBULIN; CDKN1A PROTEIN, HUMAN; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; DNA BINDING PROTEIN; ISOPROTEIN; MDM2 PROTEIN, HUMAN; MESSENGER RNA; NUCLEAR PROTEIN; ONCOPROTEIN; PROTEIN MDM2; PROTEIN P53; RNA; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN P73;

ADULT; AGED; ARTICLE; CANCER STAGING; CASE CONTROL STUDY; COMPARATIVE STUDY; GENETICS; HUMAN; MALE; METABOLISM; PATHOLOGY; PROSTATE; PROSTATE HYPERTROPHY; PROSTATE TUMOR; TUMOR SUPPRESSOR GENE;

ADULT; AGED; BETA 2-MICROGLOBULIN; CASE-CONTROL STUDIES; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA-BINDING PROTEINS; GENES, TUMOR SUPPRESSOR; HUMANS; MALE; NEOPLASM STAGING; NUCLEAR PROTEINS; PROSTATE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; RNA, MESSENGER; RNA, NEOPLASM; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 16544383365     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.12.5.1131     Document Type: Article

References (36)

1. Novelli G, Margiotti K, Chiocca AM, Spera E, Micali F and Reichardt JK: Pharmacogenetics of human androgens and prostate cancer - an update. Pharmacogenomics 5: 283-294, 2004.
2. Pienta KJ, Goodson JA and Esper PS: Epidemiology of prostate cancer: molecular and environmental clues. Urology 48: 676-683, 1996.
3. Oliai BR, Kahane H and Epstein JI: Can basal cells be seen in adenocarcinoma of the prostate? An immunohistochemical study using high molecular weight cytokeratin (clone 34betaE12) antibody. Am J Surg Pathol 26: 1151-1160, 2002.
4. Grossfeld GD and Coakley FV: Benign prostatic hyperplasia: clinical overview and value of diagnostic imaging. Radiol Clin North Am 38: 31-47, 2000.
5. Elsasser-Beile U, Przytulski B, Gierschner D, Grussenmeyer T, Katzenwadel A, Leiber C, Deckart A and Wetterauer U: Comparison of the activation status of tumor infiltrating and peripheral lymphocytes of patients with adenocarcinomas and benign hyperplasia of the prostate. Prostate 45: 1-7, 2000.
6. Kaelin WG Jr: The emerging p53 gene family. J Natl Cancer Inst 91: 594-598, 1999.
7. Stiewe T and Putzer BM: p73 in apoptosis. Apoptosis 6: 447-452, 2001.
8. MacGrogan D and Bookstein R: Tumour suppressor genes in prostate cancer. Semin Cancer Biol 8: 11-19, 1997.
9. Crundwell MC, Arkell DG, Gearty J and Phillips SM: Genetic alterations in incidentally diagnosed, transitional zone prostate cancer: a seven-year follow-up. J Urol 158: 1568-1575, 1997.
10. Schlechte HH, Schnorr D, Loning T, Rudolph BD, Pohrt UM and Loening SA: Mutation of the tumor suppressor gene p53 in human prostate and bladder cancers - investigation by temperature gradient gel electrophoresis (TGGE). J Urol 157: 1049-1053, 1997.
11. Marin MC and Kaelin WG Jr: p63 and p73: old members of a new family. Biochim Biophys Acta 1470: M93-M100, 2000.
12. Stanelle J, Stiewe T, Theseling CC, Peter M and Putzer BM: Gene expression changes in response to E2F1 activation. Nucleic Acids Res 30: 1859-1867, 2002.
13. Stiewe T and Putzer BM: Role of the p53-homologue p73 in E2Fl-induced apoptosis. Nat Genet 26: 464-469, 2000.
14. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, Minty A, Chalon P, Lelias JM, Dumont X, Ferrara P, McKeon F and Caput D: Monoallelically expressed gene related to p53 at lp36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90: 809-819, 1997.
15. Yokomizo A, Mai M, Bostwick DG, Tindall DJ, Qian J, Cheng L, Jenkins RB, Smith DI and Liu W: Mutation and expression analysis of the p73 gene in prostate cancer. Prostate 39: 94-100, 1999.
16. Zaika AI, Kovalev S, Marchenko ND and Moll UM: Overexpression of the wild-type p73 gene in breast cancer tissues and cell lines. Cancer Res 59: 3257-3263, 1999.
17. Sayan AE, Rossi M, Melino G and Knight RA: p73: in silico evidence for a putative third promoter region. Biochem Biophys Res Commun 313: 765-770, 2004.
18. Courtois S, De Fromentel CC and Hainaut P: p53 protein variants: structural and functional similarities with p63 and p73 isoforms. Oncogene 23: 631-638, 2004.
19. Wang X, Arooz T, Siu WY, Chiu CH, Lau A, Yamashita K and Poon RY: MDM2 and MDMX can interact differently with ARF and members of the p53 family. FEBS Lett 490: 202-208 2001.
20. Banin S, Moyal L, Shieh S, Taya Y, Anderson CW, Chessa L, Smorodinsky NI, Prives C, Reiss Y, Shiloh Y and Ziv Y: Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 281: 1674-1677, 1998.
21. Canman CE, Lim DS, Cimprich KA, Taya Y, Tamai K, Sakaguchi K, Appella E, Kastan MB and Siliciano JD: Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 281: 1677-1679, 1998.
22. Sherr CJ: Cancer cell cycles. Science 274: 1672-1677, 1996.
23. Morgan DO: Cyclin-dependent kinases: engines, clocks, and microprocessors. Ann Rev Cell Dev Biol 13: 261-291, 1997.
24. Winters ZE: P53 pathways involving G2 checkpoint regulators and the role of their subcellular localisation. J R Coll Surg Edinburgh 47: 591-598, 2002.
25. Melino G, De Laurenzi V and Vousden KH: p73: Friend or foe in tumorigenesis. Nat Rev Cancer 2: 605-615, 2002.
26. Gardner WA Jr and Bennett BD: The prostate - overview: recent insights and speculations. Monogr Pathol pp129-148, 1992.
27. Dennis LK and Dawson DV: Meta-analysis of measures of sexual activity and prostate cancer. Epidemiology 13: 72-79, 2002.
28. Grignon D and Sakr W: Benign prostatic hyperplasia: Is it a premalignant lesion? In Vivo 8: 415-418, 1994.
29. Bostwick DG: Prospective origins of prostate carcinoma. Prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia. Cancer 78: 330-336, 1996.
30. Roberts RO, Jacobsen SJ, Rhodes T, Girman CJ, Guess HA and Lieber MM: Natural history of prostatism: impaired health states in men with lower urinary tract symptoms. J Urol 157: 1711-1717, 1997.
31. Yu J, Zhang L, Hwang PM, Rago C, Kinzier KW and Vogelstein B: Identification and classification of p53-regulated genes. Proc Natl Acad Sci USA 96: 14517-14522, 1999.
32. Tsai KK and Yuan ZM: c-Abl stabilizes p73 by a phosphorylation-augmented interaction. Cancer Res 63: 3418-3424, 2003.
33. Prabhu NS, Somasundaram K, Satyamoorthy K, Herlyn M and El-Deiry WS: p73beta, unlike p53, suppresses growth and induces apoptosis of human papillomavirus E6-expressing cancer cells. Int J Oncol 13:5-9, 1998.
34. Moll UM, Erster S and Zaika A: p53, p63 and p73 - solos, alliances and feuds among family members. Biochim Biophys Acta 1552: 47-59, 2001.
35. Marin MC, Jost CA, Brooks LA, Irwin MS, O'Nions J, Tidy JA, James N, McGregor JM, Harwood CA, Yulug IG, Vousden KH, Allday MJ, Gusterson B, Ikawa S, Hinds PW, Crook T and Kaelin WG Jr: A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet 25: 47-54 2000.
36. Fillippovich I, Sorokina N, Gatei M, Haupt Y, Hobson K, Moallem E, Spring K, Mould M, McGuckin MA, Lavin MF and Khanna KK: Transactivation-deficient p73alpha (p73Deltaexon2) inhibits apoptosis and competes with p53. Oncogene 20: 514-522, 2001.